Biotricity

Biotricity is a remote patient monitoring company and telemedicine operator focused on preventing and managing chronic diseases. Its flagship products, Bioflux and Biotres, are wearable cardiac monitors that provide continuous ECG data recording and analysis. 

Bioflux continuously analyzes ECG information for abnormalities and transmits data to healthcare professionals for review, while Biotres is a rechargeable monitor that records up to 30 days of ECG data with remote connectivity for automated data offloading. Additionally, Biotricity offers Biocare, a disease management solution that includes analytics, AI, and various devices for arrhythmia diagnostics and chronic condition management. Its portfolio also includes Bioheart, a personal heart monitor, and Biokit, a remote monitoring kit for collecting vital data like temperature, blood pressure, and blood oxygen levels.

Further, in June 2024 , the company launched HeartSecure, a D2C heart health screening program, priced at USD 199 per kit.

In August  2021, the company’s stock began trading on the Nasdaq under the ticker symbol “BTCY.” For FY2023 , the company reported a revenue of USD 9.6 million, a 26% YoY increase. The net loss for the year also decreased 35.4% YoY to USD 19.5 million.  

Key customers and partnerships

In April 2024 , the company partnered with two notable home-based neurology and sleep apnea diagnostic companies to extend its services in cardiac diagnostics. Further in July 2024 , launched a cardiac monitoring pilot program with a prominent hospital group with 60 sites across multiple states in the US. The company also partnered with Lovell Government Services, a service-disabled veteran-owned small business, to serve federal healthcare systems in August 2024 .